SARS-CoV-2 anti-spike protein IgG concentration, ELU/mL |
Day 28 after the third dose |
23 325 (20 030–27 162); 66 |
25 317 (20 996–30 528); 66 |
20 502 (16 473–25 517); 35 |
21 980 (16 476–29 324); 33 |
26 982 (22 056–33 008); 31 |
29 161 (23 093–36 823); 33 |
Day 0 of fourth dose |
3049 (2550–3646); 66 |
3469 (2730–4407); 66 |
2532 (1974–3247); 35 |
2571 (1874–3527); 34 |
3761 (2959–4780); 31 |
4769 (3421–6648); 32 |
Day 14 after the fourth dose |
37 460 (31 996–43 857); 65 |
54 936 (46 826–64 452); 67 |
33 316 (26 942–41 198); 35 |
52 080 (41 163–65 894); 34 |
42 949 (34 148–54 019); 30 |
58 043 (46 693–72 150); 33 |
Fold change (day 14 after fourth dose vs day 28 after third dose) |
1·59 (1·41–1·78); 65 |
2·19 (1·90–2·52); 66 |
1·62 (1·35–1·95); 35 |
2·41 (1·90–3·05); 33 |
1·54 (1·35–1·76); 30 |
1·99 (1·71–2·31); 33 |
Fold change (day 14 after fourth dose vs day 0 of fourth dose) |
12·19 (10·37–14·32); 65 |
15·90 (12·92–19·58); 66 |
13·16 (10·24–16·91); 35 |
20·26 (15·09–27·21); 34 |
11·14 (9·21–13·47); 30 |
12·30 (9·39–16·11); 32 |
Cellular response (wild-type), spot forming cells per 106 PBMCs
*
Due to logistical reasons, only 50% of study sites collected cellular immunology samples (proximity to external laboratory) in the main COV-BOOST study; the cellular immunology samples after the fourth dose were collected in the immunology cohort.
|
Day 28 after the third dose |
96·03 (65·68–140·42; 35 |
111·19 (75·87–162·95); 33 |
133·33 (81·31–218·62); 19 |
113·40 (57·93–221·98); 17 |
65·04 (37·76–112·03); 16 |
108·90 (75·81–156·43); 16 |
Day 0 of fourth dose |
19·32 (10·99–33·97);36 |
35·32 (20·66–60·40); 34 |
18·85 (8·31–42·77); 20 |
42·13 (18·58–95·51); 16 |
19·93 (9·14–43·48); 16 |
30·20 (14·71–62·02); 18 |
Day 14 after the fourth dose |
112·64 (80·61–157·38); 20 |
236·95 (146·04–384·48); 20 |
141·99 (92·57–217·80); 11 |
232·98 (116·70–465·12); 11 |
84·87 (51·94–138·66); 9 |
241·91 (118·79–492·64); 9 |
Fold change (day 14 after fourth dose vs day 28 after third dose) |
1·10 (0·72–1·70); 18 |
1·69 (1·22–2·34); 19 |
1·09 (0·63–1·89); 10 |
1·16 (0·79–1·70); 11 |
1·12 (0·54–2·31); 8 |
2·83 (2·02–3·96); 8 |
Fold change (day 14 after fourth dose vs day 0 of fourth dose) |
7·32 (3·24–16·54); 19 |
6·22 (3·90–9·92); 20 |
11·07 (4·21–29·12); 11 |
6·34 (2·89–13·92); 11 |
4·14 (1·04–16·54); 8 |
6·08 (3·86–9·56); 9 |
Cellular response (beta), spot forming cells per 106 PBMCs
*
Due to logistical reasons, only 50% of study sites collected cellular immunology samples (proximity to external laboratory) in the main COV-BOOST study; the cellular immunology samples after the fourth dose were collected in the immunology cohort.
|
Day 28 after the third dose |
98·34 (72·11–134·10); 35 |
108·85 (76·90–154·07); 33 |
132·70 (87·79–200·59); 19 |
120·52 (65·57–221·54); 17 |
68·89 (45·39–104·57); 16 |
97·69 (70·62–135·12); 16 |
Day 0 of fourth dose |
18·53 (10·60–32·37); 36 |
28·35 (15·40–52·19); 34 |
16·71 (7·50–37·22); 20 |
37·69 (16·24–87·46); 16 |
21·07 (9·64–46·06); n=16 |
22·01 (9·11–53·20); 18 |
Day 14 after the fourth dose |
85·55 (54·11–135·28); 20 |
245·84 (158·84–380·50); 20 |
96·25 (55·85–165·86); 11 |
256·42 (142·42–461·65); 11 |
74·08 (33·34–164·60); 9 |
233·50 (117·10–465·64); 9 |
Fold change (day 14 after fourth dose vs day 28 after third dose) |
0·98 (0·64–1·50); 18 |
1·96 (1·36–2·82); 19 |
0·93 (0·54–1·61); 10 |
1·30 (0·91–1·87); 11 |
1·03 (0·50–2·12); 8 |
3·45 (2·10–5·69); 8 |
Fold change (day 14 after fourth dose vs day 0 of fourth dose) |
5·47 (2·30–13·02); 19 |
8·48 (4·72–15·22); 20 |
7·63 (2·51–23·17); 11 |
8·98 (4·19–19·23); 11 |
3·46 (0·85–14·08); 8 |
7·91 (3·04–20·56); 9 |
Cellular response (delta), spot forming cells per 106 PBMCs
*
Due to logistical reasons, only 50% of study sites collected cellular immunology samples (proximity to external laboratory) in the main COV-BOOST study; the cellular immunology samples after the fourth dose were collected in the immunology cohort.
|
Day 28 after the third dose |
92·48 (66·90–127·85); 35 |
104·34 (72·95–149·24); 33 |
130·31 (92·00–184·58); 19 |
114·49 (61·51–213·11); 17 |
61·55 (36·64–103·38); 16 |
94·54 (66·74–133·91); 16 |
Day 0 of fourth dose |
16·40 (9·38–28·68); 36 |
35·93 (20·29–63·62); 34 |
18·39 (8·68–38·95); 20 |
41·93 (17·99–97·78); 16 |
14·22 (6·02–33·58); 16 |
31·31 (14·19–69·08); 18 |
Day 14 after the fourth dose |
94·20 (66·92–132·60); 20 |
239·62 (155·19–369·97); 20 |
108·24 (69·20–169·28); 11 |
244·67 (141·79–422·20); 11 |
79·49 (46·55–135·72); 9 |
233·59 (111·99–487·24); 9 |
Fold change (day 14 after fourth dose vs day 28 after third dose) |
1·00 (0·68–1·49); 18 |
2·03 (1·39–2·97); 19 |
0·88 (0·56–1·38); 10 |
1·28 (0·89–1·84); 11 |
1·19 (0·59–2·40); 8 |
3·85 (2·39–6·21); 8 |
Fold change (day 14 after fourth dose vs day 0 of fourth dose) |
7·57 (3·32–17·25); 19 |
6·35 (3·51–11·49); 20 |
9·37 (3·56–24·67); 11 |
6·62 (2·87–15·25); 11 |
5·64 (1·27–25·06); 8 |
6·04 (2·48–14·68); 9 |
#Safety #immunogenicity #reactogenicity #BNT162b2 #mRNA1273 #COVID19 #vaccines #fourthdose #boosters #doses #ChAdOx1 #nCoV19 #BNT162b2 #dose #BNT162b2 #COVBOOST #multicentre #blinded #phase #randomised #trial